Clinical Trials Logo

Primary Membranous Nephropathy clinical trials

View clinical trials related to Primary Membranous Nephropathy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06120673 Not yet recruiting - Clinical trials for Primary Membranous Nephropathy

REmission in Membranous Nephropathy International Trial (REMIT)

REMIT
Start date: July 31, 2024
Phase: Phase 3
Study type: Interventional

REMIT is an investigator-initiated, international, multi-centre, prospective, randomised, open-label, parallel-group trial. A total of 224 adult participants with Primary Membranous Nephropathy (PMN) will be recruited from renal units from Australia, New Zealand Canada, Asia, Europe, United Kingdom, and other countries. Participants will be randomised to receive either corticosteroid and cyclophosphamide or obinutuzumab. The primary outcome is a ranked, composite measure based on (a) efficacy, defined as either complete or partial remission of PMN, (b) number of adverse events, and (c) quality of life.